SPOTLIGHT: Sangamo targets gene manipulation

Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a number of diseases which currently can't be treated. Report

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.